Sandrine Godichaud, Stéphanie Krisa, Baptiste Couronné, Liliane Dubuisson, Jean‐Michel Mérillon, Alexis Desmoulière, Jean Rosenbaum – 30 December 2003 – Liver myofibroblasts are major actors in the development of liver fibrosis and cancer progression. There is a large interest in drugs that might deactivate these cells. Many studies have shown that the grapevine‐derived polyphenol, trans‐resveratrol, and other stilbenes have therapeutic potential in some diseases. In this work, we have studied the effect of grapevine polyphenols on cultured human liver myofibroblasts.

Anderson S. Gaweco, Russell H. Wiesner, Michael Porayko, Vinod K. Rustgi, Sherri Yong, Raza Hamdani, James Harig, Gregorio Chejfec, Kenneth D. McClatchey, David H. Van Thiel – 30 December 2003 – Nuclear factor κB (NF‐κB) is activated during viral infection and is central to the regulation of host immune responses. The NF‐κB activation status and its morphological sources were assessed by immunohistochemistry in allograft biopsy specimens of orthotopic liver transplantation patients with recurrent hepatitis C virus (HCV).

Josep M. Llovet, Jordi Bruix – 30 December 2003

Oliver Moennikes, Albrecht Buchmann, Klaus Willecke, Otto Traub, Michael Schwarz – 30 December 2003 – Mice deficient for connexin32 (Cx32), the major gap junction forming protein in liver, are highly susceptible to hepatocarcinogenesis. Because the Cx32 gene is located on the X‐chromosome, heterozygous females show mosaicism with respect to Cx32 expression; this enables their use in studying the effect of Cx32‐deficiency in a mixed Cx32‐plus/Cx32‐minus environment in vivo.

Jean‐François Cadranel, Pierre Rufat, Françoise Degos – 30 December 2003 – A nationwide prospective study was conducted in France in 89 university and primary referral hospitals' liver units to evaluate practices of liver biopsy and the occurrence of complications. A total of 2,084 biopsies were analyzed, recording the indication, hemostasis parameters, experience of operator, route of biopsy, use of ultrasonography (US), type of hospitalization, side effects, and complications. Pain, anxiety, and discomfort were evaluated by patients by visual analogue scale (VAS).

Cheng Liao, Mujun Zhao, Hai Song, Kiyoshi Uchida, Kazunari K. Yokoyama, Tsaiping Li – 30 December 2003 – Human chromosome 8p23 is known as a region that is associated with loss of heterozygosity (LOH), which is frequently deleted in hepatocellular carcinoma (HCC) tissues. We report here the characterization of a gene for a liver‐related putative tumor suppressor (LPTS) localized at 8p23, that was isolated by allelic‐loss mapping and positional candidate cloning.

W. Ray Kim, Keith D. Lindor, Michael Malinchoc, Jan L. Petz, Roberta Jorgensen, E. Rolland Dickson – 30 December 2003 – The NIDDK‐QA instrument, developed and widely used in liver transplant recipients, assesses quality of life (QOL) in four domains, including liver disease symptoms, physical function, health satisfaction, and overall well‐being. We investigated whether the instrument may be used as a disease‐specific instrument in ambulatory patients with cholestatic liver disease.

Folke Schläger, Stephan Schaefer, Markus Metzler, Nils Gratzki, Fritz Lampert, Wolfram H. Gerlich, Reinald Repp – 30 December 2003 – Many variants of hepatitis B virus (HBV) with deletions in the viral genome have been identified. Some of these variants are indicator or even effector of a more severe course of hepatitis. These deletion mutants contribute a variable and sometimes very low proportion to the viral population.

Junpei Hayashi, Hiroshi Aoki, Kazunori Kajino, Mitsuhiko Moriyama, Yasuyuki Arakawa, Okio Hino – 30 December 2003 – Persistent hepatitis C virus (HCV) infection is associated with the development of human hepatocellular carcinoma (HCC), although the mechanism of HCV‐related hepatocarcinogenesis remains unclear. Recently, however, the close relationships between the development of HCC and the mitogen‐activated protein kinase (MAPK)/extracellular signal–regulated protein kinase (ERK) cascade have been described.

Sung Won Cho, Ki‐Baik Hahm, Jin Hong Kim – 30 December 2003 – The effect of lamivudine administration on the evolution of precore/core promoter mutation is unknown. The aim of this study was to determine the changes of precore/core promoter sequences in chronic type B hepatitis patients treated with lamivudine. Serial sera were obtained from 11 patients before, at the beginning of, and during therapy. Serum samples were polymerase chain reaction‐amplified, and nucleotide sequences of hepatitis B virus (HBV) were analyzed.